Generic drugmaker Sandoz introduced plans Thursday to begin promoting an alternative choice to the EpiPen within the U.S. early subsequent yr.
The EpiPen injector is used to halt life-threatening allergic reactions to insect bites, nuts and different meals. Model-name EpiPen, which dominates the market, has been briefly provide since spring due to manufacturing issues.
Sandoz will promote prefilled syringes with the identical medication, the hormone epinephrine, underneath the title Symjepi. The worth might be $250 for 2, with out insurance coverage.
Two generic variations of EpiPen are bought within the U.S. for $300 a pair, together with one from EpiPen vendor Mylan. The corporate began promoting its personal generic after it was blasted for repeated hikes that pushed up its checklist value from $94 to $608 for a pair of brand-name EpiPens.
What folks pay varies, although, relying on insurance coverage, reductions and the pharmacy.
MOM WITH CANCER WHOSE SEARCH FOR BONE MARROW DONOR WENT VIRAL GIVES BIRTH TO TWINS
Mylan’s injectors are made by a subsidiary of Pfizer, which is upgrading factories to repair high quality issues. That resulted in manufacturing slowdowns. Pfizer stated Thursday it is delivery some injectors and expects to ship extra within the coming months.
The shortages triggered momentary shortages of different related merchandise, together with Auvi-Q. Consequently, U.S. regulators let some producers lengthen expiration dates.
Sandoz, a part of Novartis AG., will promote syringes with an grownup dose made by Adamis Prescription drugs Corp. A kids’s model will observe.
Israel’s Teva Pharmaceutical Industries started promoting restricted portions of its new generic EpiPen within the U.S. final week.